Symptoms as a predictor of the placebo-controlled efficacy of PCI in stable coronary artery disease
Simader, Florentina A Rajkumar, Christopher A Foley, Michael J Ahmed-Jushuf, Fiyyaz Chotai, Shayna Bual, Nina Khokhar, Arif Gohar, Aisha Lampadakis, Ioannis Ganesananthan, Sashiananthan
Simader, Florentina A
Rajkumar, Christopher A
Foley, Michael J
Ahmed-Jushuf, Fiyyaz
Chotai, Shayna
Bual, Nina
Khokhar, Arif
Gohar, Aisha
Lampadakis, Ioannis
Ganesananthan, Sashiananthan
Citations
Altmetric:
Affiliation
Imperial College London; Imperial College Healthcare National Health Service (NHS) Trust' Athens Naval Hospital; Sandwell and West Birmingham NHS Trust; et al.
Other Contributors
Fairoz, Abdul
Publication date
2024-05-15
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Background: Placebo-controlled evidence from ORBITA-2 (Objective Randomised Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina-2) found that percutaneous coronary intervention (PCI) in stable coronary artery disease with little or no antianginal medication relieved angina, but residual symptoms persisted in many patients. The reason for this was unclear. Objectives: This ORBITA-2 secondary analysis investigates the relationship between presenting symptoms and disease severity (anatomic, noninvasive, and invasive ischemia) and the ability of symptoms to predict the placebo-controlled efficacy of PCI. Methods: Prerandomization symptom severity and nature were assessed using the ORBITA smartphone application and symptom and quality of life questionnaires including the World Health Organization Rose angina questionnaire (Rose). Disease severity was assessed using quantitative coronary angiography, stress echocardiography, fractional flow reserve, and instantaneous wave-free ratio. Bayesian ordinal regression was used. Results: At prerandomization, the median number of daily angina episodes was 0.8 (Q1-Q3: 0.4-1.6), 64% had Rose angina, quantitative coronary angiography diameter stenosis was 61% (Q1-Q3: 49%-74%), stress echocardiography score was 1.0 (Q1-Q3: 0.0-2.7), fractional flow reserve was 0.63 (Q1-Q3: 0.49-0.75), and instantaneous wave-free ratio was 0.78 (Q1-Q3: 0.55-0.87). There was little relationship between symptom severity and nature and disease severity: angina symptom score with quantitative coronary angiography ordinal correlation coefficient: 0.06 (95% credible interval [CrI]: 0.00-0.08); stress echocardiography: 0.09 (95% CrI: 0.02-0.10); fractional flow reserve: 0.04 (95% CrI: -0.03 to 0.07); and instantaneous wave-free ratio: 0.04 (95% CrI: -0.01 to 0.07). However, Rose angina and guideline-based typical angina were strong predictors of placebo-controlled PCI efficacy (angina symptom score: OR: 1.9; 95% CrI: 1.6-2.1; probability of interaction [PrInteraction] = 99.9%; and OR: 1.8; 95% CrI: 1.6-2.1; PrInteraction = 99.9%, respectively). Conclusions: Although symptom severity and nature were poorly associated with disease severity, the nature of symptoms powerfully predicted the placebo-controlled efficacy of PCI.
Citation
Simader FA, Rajkumar CA, Foley MJ, Ahmed-Jushuf F, Chotai S, Bual N, Khokhar A, Gohar A, Lampadakis I, Ganesananthan S, Pathimagaraj RH, Nowbar A, Davies JR, Keeble TR, O'Kane PD, Haworth P, Routledge H, Kotecha T, Spratt JC, Williams R, Nijjer SS, Sen S, Curzen N, Sinha M, Howard JP, Cole G, Harrell FE Jr, Francis DP, Shun-Shin MJ, Al-Lamee RK; ORBITA-2 Investigators. Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease. J Am Coll Cardiol. 2024 Jul 2;84(1):13-24. doi: 10.1016/j.jacc.2024.04.016
Type
Article